Purpose: The aim of this study was to evaluate the effect of combined (68)Ga and (18)F-FDG PET/CT on treatment management for patients with pancreatic neuroendocrine tumor (PNET). Methods: Between January 2012 and April 2014, 49 consecutive patients with a cytologically and/or histologically proven diagnosis of PNET underwent combined (68)Ga and (18)FDG PET/CT on the same day. Results: The study group consisted of 21 males and 28 females with a median age of 59 years. Disease detection was achieved in 48 out of the 49 cases with (68)Ga imaging, and in 36 of the 49 cases with (18)FDG PET/CT. These results corresponded to sensitivities of 98% for (68)Ga versus 73% for (18)FDG PET/CT. Patients with NET-G1/NET-G2 had a positive (68)Ga and negative (18)FDG PET/CT in 13 cases, whereas both (68)Ga and (18)FDG PET/CT were positive in 27 cases. Patients with NEC-G3 were positive by both (68)Ga and (18)FDG PET/CT in 7 cases and positive only by (18)FDG in 1 case. Another NEC-G3 patient was only positive by (68)Ga PET/CT. The median Ki67 was 7% for (68)Ga PET/CT-positive tumors and 10% for tumors with both (68)Ga and (18)FDG PET/CT positivity (p = 0.130). Half of the patients with a prevalent uptake of (18)FDG (n = 7) had an NEC-G3 compared with 12% of patients with a prevalent uptake of (68)Ga (p = 0.012). There were no significant differences between patients with positive (68)Ga and those with positive (18)FDG with regards to treatment choice. Conclusions: The association of (18)FDG slightly increases sensitivity of (68)Ga PET/CT alone in the diagnosis of PNET. A combined dual tracer PET/CT does not influence the choice of treatment strategy.

Purpose: The aim of this study was to evaluate the effect of combined 68Ga and 18F-FDG PET/CT on treatment management for patients with pancreatic neuroendocrine tumor (PNET). Methods: Between January 2012 and April 2014, 49 consecutive patients with a cytologically and/or histologically proven diagnosis of PNET underwent combined 68Ga and 18FDG PET/CT on the same day. Results: The study group consisted of 21 males and 28 females with a median age of 59 years. Disease detection was achieved in 48 out of the 49 cases with 68Ga imaging, and in 36 of the 49 cases with 18FDG PET/CT. These results corresponded to sensitivities of 98% for 68Ga versus 73% for 18FDG PET/CT. Patients with NET-G1/NET-G2 had a positive 68Ga and negative 18FDG PET/CT in 13 cases, whereas both 68Ga and 18FDG PET/CT were positive in 27 cases. Patients with NEC-G3 were positive by both 68Ga and 18FDG PET/CT in 7 cases and positive only by 18FDG in 1 case. Another NEC-G3 patient was only positive by 68Ga PET/CT. The median Ki67 was 7% for 68Ga PET/CT-positive tumors and 10% for tumors with both 68Ga and 18FDG PET/CT positivity (p = 0.130). Half of the patients with a prevalent uptake of 18FDG (n = 7) had an NEC-G3 compared with 12% of patients with a prevalent uptake of 68Ga (p = 0.012). There were no significant differences between patients with positive 68Ga and those with positive 18FDG with regards to treatment choice. Conclusions: The association of 18FDG slightly increases sensitivity of 68Ga PET/CT alone in the diagnosis of PNET. A combined dual tracer PET/CT does not influence the choice of treatment strategy.

Purpose: The aim of this study was to evaluate the effect of combined 68Ga and 18F-FDG PET/CT on treatment management for patients with pancreatic neuroendocrine tumor (PNET). Methods: Between January 2012 and April 2014, 49 consecutive patients with a cytologically and/or histologically proven diagnosis of PNET underwent combined 68Ga and 18FDG PET/CT on the same day. Results: The study group consisted of 21 males and 28 females with a median age of 59 years. Disease detection was achieved in 48 out of the 49 cases with 68Ga imaging, and in 36 of the 49 cases with 18FDG PET/CT. These results corresponded to sensitivities of 98% for 68Ga versus 73% for 18FDG PET/CT. Patients with NET-G1/NET-G2 had a positive 68Ga and negative 18FDG PET/CT in 13 cases, whereas both 68Ga and 18FDG PET/CT were positive in 27 cases. Patients with NEC-G3 were positive by both 68Ga and 18FDG PET/CT in 7 cases and positive only by 18FDG in 1 case. Another NEC-G3 patient was only positive by 68Ga PET/CT. The median Ki67 was 7% for 68Ga PET/CT-positive tumors and 10% for tumors with both 68Ga and 18FDG PET/CT positivity (p = 0.130). Half of the patients with a prevalent uptake of 18FDG (n = 7) had an NEC-G3 compared with 12% of patients with a prevalent uptake of 68Ga (p = 0.012). There were no significant differences between patients with positive 68Ga and those with positive 18FDG with regards to treatment choice. Conclusions: The association of 18FDG slightly increases sensitivity of 68Ga PET/CT alone in the diagnosis of PNET. A combined dual tracer PET/CT does not influence the choice of treatment strategy.

The role of combined Ga-DOTANOC and 18FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors / Partelli, Stefano; Rinzivillo, Maria; Maurizi, Angela; Panzuto, Francesco; Salgarello, Matteo; Polenta, Vanessa; Delle Fave, Gianfranco; Falconi, Massimo. - In: NEUROENDOCRINOLOGY. - ISSN 0028-3835. - STAMPA. - 100:4(2014), pp. 293-299. [10.1159/000368609]

The role of combined Ga-DOTANOC and 18FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors

Rinzivillo, Maria;Maurizi, Angela;Panzuto, Francesco;Delle Fave, Gianfranco;
2014

Abstract

Purpose: The aim of this study was to evaluate the effect of combined 68Ga and 18F-FDG PET/CT on treatment management for patients with pancreatic neuroendocrine tumor (PNET). Methods: Between January 2012 and April 2014, 49 consecutive patients with a cytologically and/or histologically proven diagnosis of PNET underwent combined 68Ga and 18FDG PET/CT on the same day. Results: The study group consisted of 21 males and 28 females with a median age of 59 years. Disease detection was achieved in 48 out of the 49 cases with 68Ga imaging, and in 36 of the 49 cases with 18FDG PET/CT. These results corresponded to sensitivities of 98% for 68Ga versus 73% for 18FDG PET/CT. Patients with NET-G1/NET-G2 had a positive 68Ga and negative 18FDG PET/CT in 13 cases, whereas both 68Ga and 18FDG PET/CT were positive in 27 cases. Patients with NEC-G3 were positive by both 68Ga and 18FDG PET/CT in 7 cases and positive only by 18FDG in 1 case. Another NEC-G3 patient was only positive by 68Ga PET/CT. The median Ki67 was 7% for 68Ga PET/CT-positive tumors and 10% for tumors with both 68Ga and 18FDG PET/CT positivity (p = 0.130). Half of the patients with a prevalent uptake of 18FDG (n = 7) had an NEC-G3 compared with 12% of patients with a prevalent uptake of 68Ga (p = 0.012). There were no significant differences between patients with positive 68Ga and those with positive 18FDG with regards to treatment choice. Conclusions: The association of 18FDG slightly increases sensitivity of 68Ga PET/CT alone in the diagnosis of PNET. A combined dual tracer PET/CT does not influence the choice of treatment strategy.
2014
Purpose: The aim of this study was to evaluate the effect of combined 68Ga and 18F-FDG PET/CT on treatment management for patients with pancreatic neuroendocrine tumor (PNET). Methods: Between January 2012 and April 2014, 49 consecutive patients with a cytologically and/or histologically proven diagnosis of PNET underwent combined 68Ga and 18FDG PET/CT on the same day. Results: The study group consisted of 21 males and 28 females with a median age of 59 years. Disease detection was achieved in 48 out of the 49 cases with 68Ga imaging, and in 36 of the 49 cases with 18FDG PET/CT. These results corresponded to sensitivities of 98% for 68Ga versus 73% for 18FDG PET/CT. Patients with NET-G1/NET-G2 had a positive 68Ga and negative 18FDG PET/CT in 13 cases, whereas both 68Ga and 18FDG PET/CT were positive in 27 cases. Patients with NEC-G3 were positive by both 68Ga and 18FDG PET/CT in 7 cases and positive only by 18FDG in 1 case. Another NEC-G3 patient was only positive by 68Ga PET/CT. The median Ki67 was 7% for 68Ga PET/CT-positive tumors and 10% for tumors with both 68Ga and 18FDG PET/CT positivity (p = 0.130). Half of the patients with a prevalent uptake of 18FDG (n = 7) had an NEC-G3 compared with 12% of patients with a prevalent uptake of 68Ga (p = 0.012). There were no significant differences between patients with positive 68Ga and those with positive 18FDG with regards to treatment choice. Conclusions: The association of 18FDG slightly increases sensitivity of 68Ga PET/CT alone in the diagnosis of PNET. A combined dual tracer PET/CT does not influence the choice of treatment strategy.
Purpose: The aim of this study was to evaluate the effect of combined (68)Ga and (18)F-FDG PET/CT on treatment management for patients with pancreatic neuroendocrine tumor (PNET). Methods: Between January 2012 and April 2014, 49 consecutive patients with a cytologically and/or histologically proven diagnosis of PNET underwent combined (68)Ga and (18)FDG PET/CT on the same day. Results: The study group consisted of 21 males and 28 females with a median age of 59 years. Disease detection was achieved in 48 out of the 49 cases with (68)Ga imaging, and in 36 of the 49 cases with (18)FDG PET/CT. These results corresponded to sensitivities of 98% for (68)Ga versus 73% for (18)FDG PET/CT. Patients with NET-G1/NET-G2 had a positive (68)Ga and negative (18)FDG PET/CT in 13 cases, whereas both (68)Ga and (18)FDG PET/CT were positive in 27 cases. Patients with NEC-G3 were positive by both (68)Ga and (18)FDG PET/CT in 7 cases and positive only by (18)FDG in 1 case. Another NEC-G3 patient was only positive by (68)Ga PET/CT. The median Ki67 was 7% for (68)Ga PET/CT-positive tumors and 10% for tumors with both (68)Ga and (18)FDG PET/CT positivity (p = 0.130). Half of the patients with a prevalent uptake of (18)FDG (n = 7) had an NEC-G3 compared with 12% of patients with a prevalent uptake of (68)Ga (p = 0.012). There were no significant differences between patients with positive (68)Ga and those with positive (18)FDG with regards to treatment choice. Conclusions: The association of (18)FDG slightly increases sensitivity of (68)Ga PET/CT alone in the diagnosis of PNET. A combined dual tracer PET/CT does not influence the choice of treatment strategy.
18FDG; 68Gallium; Neuroendocrine neoplasm; Pancreatic neuroendocrine tumor; Positron emission tomography; Aged; Female; Fluorodeoxyglucose F18; Gallium Radioisotopes; Humans; Male; Middle Aged; Neuroendocrine Tumors; Organometallic Compounds; Pancreatic Neoplasms; Positron-Emission Tomography; Sensitivity and Specificity; Tomography, X-Ray Computed; Endocrinology; Endocrinology, Diabetes and Metabolism; Endocrine and Autonomic Systems; Cellular and Molecular Neuroscience
01 Pubblicazione su rivista::01a Articolo in rivista
The role of combined Ga-DOTANOC and 18FDG PET/CT in the management of patients with pancreatic neuroendocrine tumors / Partelli, Stefano; Rinzivillo, Maria; Maurizi, Angela; Panzuto, Francesco; Salgarello, Matteo; Polenta, Vanessa; Delle Fave, Gianfranco; Falconi, Massimo. - In: NEUROENDOCRINOLOGY. - ISSN 0028-3835. - STAMPA. - 100:4(2014), pp. 293-299. [10.1159/000368609]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/807092
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 15
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 46
social impact